Expression and prognostic impact of in colorectal adenocarcinoma.

Background: Colorectal adenocarcinoma (COAD) is a malignant tumor with high mortality and low 5-year survival rate. Voltage-dependent anion channel 3 (VDAC3) is the least understood isoform of voltage-dependent anion-selective channels in the mitochondrial outer membrane. In this thesis, we aimed to investigate the prognostic value of and provide new insights into colon adenocarcinoma.

Methods: We utilized The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) database, Human Protein Atlas online database, and the University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) database to analyze expression in COAD and assess patient survival rates. Univariate and multivariate Cox regression analyses were employed to evaluate 's prognostic significance for COAD. Gene set variation analysis (GSVA) was utilized to explore COAD-related signaling pathways associated with . Additionally, we predicted the relationship between expression and anticancer drug sensitivity using the CellMiner database.

Results: In the TCGA database, demonstrated elevated expression levels in COAD, which was further validated by findings from the GEO database. Survival analysis conducted using Kaplan-Meier (K-M) curves highlighted that the patients with decreased expression exhibited significantly shorter overall survival durations. expression demonstrated correlation with COAD pathological stage. gene mutation was linked to COAD outcomes. Cox regression analysis showed that was an independent predictor. In addition, GSVA analysis showed that was closely related to mitochondria-related biological processes and involved in the occurrence and development of mitochondria-related diseases. Finally, analysis of the CellMiner database predicted that expression was positively correlated with chelerythrine and cladribine, but negatively correlated with Ergenyl.

Conclusions: Our study suggests that may be a potential biomarker for early diagnosis, prognosis, and treatment of COAD.